February 23, 2026

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

Conexiant

February 17, 2026

CKD Markers Linked to Cognitive Risk

In adults with chronic kidney disease, higher proteinuria and lower estimated glomerular filtration rate are associated with increased risk of incident cognitive impairment.

Conexiant

February 12, 2026

FDA Approves HRT Label Changes

The agency cited updated evidence in revising hormone therapy safety language.

Conexiant

February 12, 2026

Treating Loneliness as a Clinical Risk

Trial informs scalable behavioral health approaches for socially isolated older adults

Conexiant

February 12, 2026

Insomnia Outcomes May Vary by Measurement Method 

Smartphone-based symptom tracking highlights gaps in how insomnia treatments are evaluated.

Conexiant

February 04, 2026

Plasma pTau217 Cutoffs for Clinical Use

Researchers assess how biological factors influence plasma biomarker interpretation for amyloid detection.

Conexiant

February 04, 2026

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.

KFF Health News

January 30, 2026

Alzheimer Biomarkers Higher in Women

Researchers identify sex-specific differences in amyloid, tau, and brain structure during the seventh decade of life.

Conexiant

January 27, 2026

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.

Conexiant